Could Celgene Shake Up the CAR-T Market? – Motley Fool
Motley Fool |
Could Celgene Shake Up the CAR–T Market?
Motley Fool The current CAR-T party of two might have a couple of new companions on the way. And those new entrants could bring some excitement to the party. Only two chimeric antigen T–cell receptor (CAR-T) therapies are currently approved by the FDA — Novartis’ … Celgene Presents Data on CAR T Therapy, Revlimid & PomalystNasdaq bluebird shares recover after slump following ASCO CAR–T data presentationMedCity News Celgene (CELG), bluebird bio (BLUE) Phase I Study of bb2121 Demonstrates Deep and Durable Responses at ASCOStreetInsider.com |
R & D Magazine |
ASCO 2018: More Lung Cancer Patients Could Benefit From Immunotherapy Over Chemo
R & D Magazine A new study demonstrates that immunotherapeutic agent pembrolizumab (Keytruda) is more effective than chemotherapy as a first-line treatment for most patients with a common type of lung cancer, regardless of patients’ expression of PD-L1, a protein … |
|
A change in bacteria’s genetic code holds promise of longer-lasting drugs
Science Daily “We have been able to expand the genetic code to make new, biomedically relevant proteins,” said Andrew Ellington, associate director of the Center for Systems and Synthetic Biology and a professor of molecular biosciences who co-authored the study. |